Plaqueerosion

Mitarbeiterinnen und Mitarbeiter

Carolina Neu, M. Sc.
Wissenschaftliche Mitarbeiterin
Tel.: 0241 80-35229
cneuukaachende

Rahma Shahin, M. Sc.
Biologisch-Technische Assistentin
Tel.: 0241 80-35646
rshahinukaachende

• Evaluation geeigneter Biomarker zur nicht-invasiven Differenzierung von Plaqueerosion und Plaque Ruptur mit Hilfe endothelialer Progenitorzellen (EPCs) und zirkulierender Endothelzellen (CECs)
• Untersuchung genetischer Faktoren von Plaqueerosion
• Entwicklung eines in vitro Modells zur Plaqueerosion

Ausgewählte Publikationen:

Erstautor:

• Cornelissen A, Vogt FJ. The effects of stenting on coronary endothelium from a molecular biological view: Time for improvement? J Cell Mol Med. 2019; 23(1): 39-46.
• Cornelissen A, Jinnouchi H, Sakamoto A, et al. Evaluation and Management of the Vulnerable Plaque. Curr Cardiovasc Risk Rep. 2019 May;13(6).
• Cornelissen A, Guo L, Sakamoto A, Virmani R, Finn AV. New insights into the role of iron in inflammation and atherosclerosis. EBioMedicine. 2019 Sep;47:598-606.doi: 10.1016/j.ebiom.2019.08.014.
• Cornelissen A, Simsekyilmaz S, Liehn E, et al. Apolipoprotein E deficient rats generated via zinc-finger nucleases exhibit pronounced in-stent restenosis. Sci Rep. 2019 Dec 3;9(1):18153. doi: 10.1038/s41598-019-54541-z.
• Cornelissen A, Guo L, Sakamoto A, et al. Histopathologic and physiologic effect of bifurcation stenting: current status and future perspectives. Expert Rev Med Devices. 2020 Mar;17(3):189-200. doi: 10.1080/17434440.2020.1733410.
• Cornelissen A, Florescu R, Schaaps N, et al. Implantation of Human-sized Coronary Stents into Rat Abdominal Aorta Using a Trans-femoral Access. J Vis Exp 2020. doi: 10.3791/61442
• Cornelissen A, Fuller D, et al. APOL1 Genetic Variants are Associated with Increased Risk of Coronary Atherosclerotic Plaque Rupture in African Americans. Arterioscler Thromb Vasc Biol. 2021 Jul;41(7):2201 – 2214. doi: 10.1161/ATVBAHA.120.315788.
• Cornelissen A, Florescu R, Kneizeh K, et al. Intact fibroblast growth factor 23 levels and outcome prediction in patients with acute heart failure. Sci Rep. 2021 Jul 30;11(1):15507. doi: 10.1038/s41598-021-94780-7.
• Cornelissen A, Guo L, Fernandez R, et al. Endothelial recovery in bare metal and drug- eluting stents on a single-cell level. Arterioscler Thromb Vasc Biol. 2021 Aug; 41(8):2277-2292. doi: 10.1161/ATVBAHA.121.316472.
• Cornelissen A, Florescu R, Kneizeh K, et al. Fibroblast Growth Factor 23 and Outcome Prediction in Patients with Acute Myocardial Infarction. J Clin Med. 2022 Jan 25; 11(3):601. doi: 10.3390/jcm11030601
• Cornelissen A, Kutyna M, Cheng Q, et al. Effects of Simulated COVID-19 Cytokine Storm on Stent Thrombogenicity. Cardiovasc Revasc Med. 2022 Feb; 25:129-138. doi: 10.1016/j.carrev.2021.03.023.
• Cornelissen A, Sakamoto A, Sato Y, et al. COBRA PzFTM coronary stent in clinical and preclinical studies: setting the stage for new antithrombotic strategies? Future Cardiol. 2022 Mar; 18(3):207-217. doi: 10.2217/fca-2021-0057.
• Thiele K*, Cornelissen A* (equal contribution), Florescu R, et al. The role of vitamin D3 as independent predicting marker for one-year mortality in patients with acute heart failure. J Clin Med. 2022 May 12;11(10):2733. doi: 10.3390/jcm11102733.
• Cornelissen A, Guo L, Neally SJ, et al. Relationships Between Neighborhood Disadvantage and Cardiovascular Findings at Autopsy In Subjects with Sudden Death. Am Heart J. 2023 Feb;256:37-50. doi: 10.1016/j.ahj.2022.10.086. 
• Cornelissen A, Gadhoke N, Ryan K, et al. Polygenic Risk Score and Autopsy-proven Atherosclerosis. In revision for Arterioscler Thromb Vasc Biol.

Weitere:

• Tschoeke B, Flanagan TC, Cornelissen A, Koch S, Roehl A, Sriharwoko M, et al. Development of a composite degradable/nondegradable tissue-engineered vascular graft. Artif Organs. 2008; 32(10): 800-9. doi: 10.1111/j.1525-1594.2008.00601.x.
• Guo L, Fernandez R, Sakamoto A, Cornelissen A, Paek KH, Lee PJ, et al. Vascular Permeability Assay in Human Coronary and Mouse Brachiocephalic Arteries. Bio Protoc. 2018; 8(20).
• Harari E, Guo L, Smith SL, Paek KH, Fernandez R, Sakamoto A, Mori H, Kutyna MD, Habib A, Torii S, Cornelissen A, et al. Direct Targeting of the mTOR (Mammalian Target of Rapamycin) Kinase Improves Endothelial Permeability in Drug-Eluting Stents- Brief Report. Arteriosclerosis, thrombosis, and vascular biology. 2018; 38(9): 2217-24.
• Guo L, Sakamoto A, Cornelissen A, Hong CC, Finn AV. Ironing-Out the Role of Hepcidin in Atherosclerosis. Arterioscler Thromb Vasc Biol. 2019 Mar;39(3):303-305. doi: 10.1161/ATVBAHA.119.312369
• Torii S, Jinnouchi H, Sakamoto A, Kutyna M, Cornelissen A, et al. Drug-eluting stents: insights from preclinical and pathology studies. Nat Rev Cardiol. 2020 Jan;17(1):37-51. doi: 10.1038/s41569-019-0234-x.
• Jinnouchi H, Guo L, Sakamoto A, Torii S, Sato Y, Cornelissen A, et al. Diversity of macrophage phenotypes and responses in atherosclerosis. Cell Mol Life Sci. 2020; 77(10):1919-1932. doi: 10.1007/s00018-019-03371-3.
• Jain M, Dhanesha N, Doddapattar P, Chorawala MR, Nayak MK, Cornelissen A, et al. Smooth muscle cell-specific fibronectin-EDA mediates phenotypic switching and neointimal hyperplasia. J Clin Invest. 2020 Jan 2;130(1):295-314. doi: 10.1172/JCI124708.
• Torii S, Jinnouchi H, Sakamoto A, Mori H, Park J, Amoa FC, Sawan M, Sato Y, Cornelissen A, et al. Vascular responses to coronary calcification following implantation of newer-generation drug-eluting stents in humans: impact on healing. Eur Heart J. 2020 Feb 1;41(6):786-796. doi: 10.1093/eurheartj/ehz850.
• Guo L, Cornelissen A, Sakamoto A, Finn AV. Making Novel Genetic Associations With Carotid Intima-Media Thickness Using the UK Biobank. Arterioscler Thromb Vasc Biol. 2020 Feb;40(2):297-300. doi: 10.1161/ATVBAHA.119.313784.
• Kuntz SH, Torii S, Jinnouchi H, Cornelissen A, et al. Pathology and Multimodality Imaging of Acute and Chronic Femoral Stenting in Humans. JACC Cardiovasc Interv. 2020 Feb 24;13(4):418-427. doi: 10.1016/j.jcin.2019.10.060.
• Jinnouchi H, Otsuka F, Sato Y, Bhoite RR, Sakamoto A, Torii S, Yahagi K, Cornelissen A, et al. Healthy Strut Coverage After Coronary Stent Implantation: An Ex Vivo Human Autopsy Study. Circ Cardiovasc Interv. 2020 May;13(5):e008869. doi: 10.1161/CIRCINTERVENTIONS.119.008869
• Jinnouchi H, Guo L, Sakamoto A, Sato Y, Cornelissen A, et al. Advances in mammalian target of rapamycin kinase inhibitors: application to devices used in the treatment of coronary artery disease. Future Med Chem. 2020 Jun;12(12):1181-1195. doi: 10.4155/fmc-2019-0304.
• Sakamoto A, Torii S, Jinnouchi H, Guo L, Cornelissen A, et al. Comparison of endothelial barrier functional recovery after implantation of a novel biodegradable polymer sirolimus-eluting stent in comparison to durable and biodegradable polymer everolimus-eluting stents. Cardiovasc Revasc Med. 2020 Aug 13:S1553- 8389(20)30481-4. doi: 10.1016/j.carrev.2020.08.012.
• Jinnouchi H, Sato Y, Sakamoto A, Cornelissen A, et al. Calcium deposition within coronary atherosclerotic lesions: Implications for plaque stability. Atherosclerosis. 2020 Aug;306:85-95. doi: 10.1016/j.atherosclerosis.2020.05.017.
• Jinnouchi H, Sato Y, Torii S, Sakamoto A, Cornelissen A, et al. Detection of cholesterol crystals by optical coherence tomography. EuroIntervention. 2020 Aug 28;16(5):395- 403. doi: 10.4244/EIJ-D-20-00202.
• Sakamoto A, Kawakami R, Kawai K, Gianatti A, Pellegrini D, Kutys R, Guo L, Mori M, Cornelissen A, et al. ACE2 (Angiotensin-Converting Enzyme 2) and TMPRSS2 (Transmembrane Serine Protease 2) Expression and Localization of SARS-CoV2 Infection in the Human Heart. Arterioscler Thromb Vasc Biol. 2020 Oct 22:ATVBAHA120315229. doi: 10.1161/ATVBAHA.120.315229.
• Kuntz SH, Jinnouchi H, Kutyna M, Torii S, Cornelissen A, et al. Co-Registration of Peripheral Atherosclerotic Plaques Assessed by Conventional CT Angiography, MicroCT and Histology in Patients with Chronic Limb Threatening Ischaemia. Eur J Vasc Endovasc Surg. 2020 Nov 10:S1078-5884(20)30778-4. doi: 10.1016/j.ejvs.2020.08.037.
• Kawakami R, Sakamoto A, Kawai K, Gianatti A, Pellegrini D, Nasr A, Kutys B, Guo L, Cornelissen A, et al. Pathological Evidence for SARS-CoV-2 as a Cause of Myocarditis: JACC Review Topic of the Week. J Am Coll Cardiol. 2021 Jan 26; 77(3):314-325. doi: 10.106/j.jacc.2020.11.031.
• Sato Y, Kawakami R, Jinnouchi H, Sakamoto A, Cornelissen A, et al. Comprehensive Assessment of Human Accessory Renal Artery Periarterial Renal Sympathetic Nerve Distribution. JACC Cardiovasc Interv. 2021 Feb 8; 14(3):304-315. doi: 10.1016/j.jcin.2020.09.043.
• Jinnouchi H, Sato Y, Cheng Q, Janifer C, Kutyna M, Cornelissen A, et al. Thromboresistance and endothelial healing in polymer-coated versus polymer-free drug-eluting stents: Implications for short-term dual anti-platelet therapy. Int J Cardiol. 2021 Mar 15;327:52-57. doi: 10.1016/j.jicard.2020.11.030.
• Pellegrini D, Kawakami R, Guagliumi G, Sakamoto A, Kawai K, Gianatti A, Nasr A, Kutys R, Guo L, Cornelissen A, et al. Microthrombi as a Major Cause of Cardiac Injury in COVID-19: A Pathologic Study. Circulation. 2021 Mar 9; 143(10):1031-1042. doi: 10.1161/CIRCULATIONAHA.120.051828.
• Torii S, Sato Y, Otsuka F, Kolodgie FD, Jinnouchi H, Sakamoto A, Park J, Yahagi K, Sakakura K, Cornelissen A, et al. Eruptive Calcified Nodules as a Potential Mechanism of Acute Coronary Thrombosis and Sudden Death. J Am Coll Cardiol. 2021 Apr 6;77(13):1599-1611. Doi: 10.1016/j.jacc.2021.02.016.
• Sakamoto A, Torii S, Jinnouchi H, Fuller D, Cornelissen A, et al. Vascular Response of a Polymer-Free Paclitaxel-Coated Stent (Zilver PTX) versus a Polymer-Coated Paclitaxel-Eluting Stent (Eluvia) in Healthy Swine Femoropopliteal Arteries. J Vasc Interv Radiol. 2021 Jun;32(6):792-801.e5. doi: 10.1016/j.jvir.2021.02.014.
• Silver MJ, Kawakami R, Jolly MA, Huff CM, Phillips JA, Sakamoto A, Kawai K, Kutys B, Guo L, Cornelissen A, et al. Histopathologic analysis of extracted thrombi from deep venous thrombosis and pulmonary embolism: Mechanisms and timing. Catheter Cardiovasc interv. 2021 Jun 1; 97(7):1422-1429. doi: 10.1002/ccd.29500.
• Jinnouchi H, Kutyna M, Torii S, Cheng Q, Sakamoto A, Guo L, Cornelissen A, et al. Comparison of Acute Thrombogenicity and Albumin Adsorption in Three Different Durable Polymer Coronary Drug-Eluting Stents. EuroIntervention. 2021 Jun 25; 17(3):248-256. doi: 10.4244/EIJ-D-19-00938.
• Sato Y, Kawakami R, Sakamoto A, Cornelissen A, et al. ParadiseTM Ultrasound Renal Denervation System for the treatment of hypertension. Future Cardiol. 2021 Sep; 17(6):931-944. doi: 10.2217/fca-2020-0228.
• Sato Y, Jinnouchi H, Kolodgie FD, Cheng Q, Janifer C, Kutyna M, Sakamoto A, Cornelissen A, et al. Acute thrombogenicity of fluoropolymer coated stents versus competitive drug-eluting stents under single antiplatelet therapy. Int J Cardiol. 2021 Sep 1; 338:42-49. doi: 10.1016/j.ijcard.2021.06.034.
• Guo L, Torii S, Fernandez R, Braumann RE, Fuller DT, Paek KH, Gadhoke NV, Maloney KA, Harris K, Mayhew CM, Zarpak R, Stevens LM, Gaynor BJ, Jinnouchi H, Sakamoto A, Sato Y, Mori H, Kutyna MD, Lee PJ, Weinstein LM, Collado-Rivera CJ, Ali BB, Atmakuri DR, Dhingra R, Finn ELB, Bell MW, Lynch M, Cornelissen A, et al. Genetic Variants Associated With Unexplained Sudden Cardiac Death in Adult White and African American Individuals. JAMA Cardiol. 2021 Sep 1; 6(9):1013-1022. doi: 10.1001/jamacardio.2021.1573.
• Sakamoto A, Sato Y, Kawakami R, Cornelissen A, et al. Risk prediction of in-stent restenosis among patients with coronary drug-eluting stents: current clinical approaches and challenges. Expert Rev Cardiovasc Ther. 2021 Sep; 19(9):801-816. doi: 10.1080/14779072.2021.1856657.
• Sato Y, Kawakami R, Sakamoto A, Cornelissen A, et al. Efficacy and safety of cerebral embolic protection systems during transcatheter aortic valve replacement: a review of current clinical findings. Expert Rev Cardiovasc Ther. 2021 Aug;19(8):725-737. doi: 10.1080/14779072.2021.1955346.
• Mori M, Sakamoto A, Sato Y, Kawakami R, Kawai K, Cornelissen A, et al. Overcoming challenges in refining the current generation of coronary stents. Expert Rev Cardiovasc Ther. 2021 Nov; 19(11):1013-1028. doi: 10.1080/14779072.2021.2013810.
• Sato Y, Kawakami R, Sakamoto A, Cornelissen A, et al. Sex Differences in Coronary Atherosclerosis. Curr Atherosclero Rep. 2022 Jan; 24(1):23-32. doi: 10.1007/s11883-022-00980-5.
• Kawakami R, Gada H, Rinaldi MJ, Nazif TM, Leon MB, Kapadia S, Krishnaswamy A, Sakamoto A, Sato Y, Mori M, Kawai K, Cornelissen A, et al. Characterization of Cerebral Embolic Capture Using the SENTINEL Device During Transcatheter Aortic Valve Implantation in Low to Intermediate-Risk Patients: The SENTINEL-LIR Study. Circ Cardiovasc Interv. 2022 Apr; 15(4):e011358. doi: 10.1161/CIRCINTERVENTIONS.121.011358.
• Kawai K, Sato Y, Kawakami R, Sakamoto A, Cornelissen A, Mori M, Ghosh S, Kutys R, Virmani R, Finn AV. Generalized Arterial Calcification of Infancy (GACI): Optimizing Care with a Multidisciplinary Approach J Multidiscip Healthc. 2022 Jun 1;15:1261-1276. doi: 10.2147/JMDH.S251861. eCollection 2022.
• Florescu R, Liehn E, Schaaps N, Schröder J, Almalla M, Mause S, Cornelissen A, Vogt F. Dose-dependent impact of statin therapy intensity on circulating progenitor cells in patients undergoing percutaneous coronary intervention for the treatment of acute versus chronic coronary syndrome. PLoS One. 2022 May 19;17(5):e0267433. doi: 10.1371/journal.pone.0267433. eCollection 2022
• Sakamoto A, Kawakami R, Mori M, Guo L, Paek KH, Mosquera JV, Cornelissen A, et al. CD163+ macrophages restrain vascular calcification, promoting the development of high-risk plaque. JCI Insight. 2023 Jan 31:e154922. doi:10.1172/jci.insight.154922.

For a complete reference list please see PubMed* Link

• Förderung im Rahmen des NRW Rückkehrprogramms

• Lehrtätigkeit an der Medizinischen Fakultät im Rahmen des Modellstudiengangs Medizin

Wir sind ständig auf der Suche nach talentierten Wissenschaftlerinnen und Wissenschaftler mit Interesse an gängigen molekularbiologischen Methoden sowie an der Entwicklung von in vitro Modellen zur Erforschung der Rolle von Endothelzellen bei der Arterioskleroseentstehung und –progression unter physiologischen und pathologischen hämodynamischen Bedingungen. Arbeitspakete für Masterarbeiten oder medizinische Doktorarbeiten können individuell vereinbart werden. Bei Interesse senden Sie bitte Ihren Lebenslauf und ein Motivationsschreiben an Dr. med. Anne Glitz (aglitzukaachende).